OUR SCIENCE

Immunology

Unlocking Immunology To Change The Lives of Patients

TH104 represents a novel advancement in pharmaceutical innovation, serving as a cornerstone for our lead clinical program. This product is meticulously crafted by embedding a drug onto a proprietary transmucosal buccal film, designed to adhere seamlessly to the inner lining of the mouth. This unique formulation of TH104 positions it as an optimal candidate for addressing a spectrum of chronic liver-related diseases and other pruritogenic inflammatory conditions.

The Power of Dual Receptor Targeting

next
TH104 represents a pioneering advancement in pharmaceutical innovation, serving as a cornerstone in our comprehensive science and clinical program. This product is meticulously crafted, employing a groundbreaking approach by encapsulating the drug onto a proprietary transmucosal buccal film, designed to adhere seamlessly to the inner lining of the mouth. The unique formulation of TH104 boasts exceptional qualities, positioning it as an optimal candidate for addressing a spectrum of liver-related ailments and other pruritogenic inflammatory conditions.

Kappa-opiod receptors (KORs) and mu-opioid receptors (MORs) have been implicated in both the suppression and promotion of itch, respectively, and pronounced in conditions such as liver and atopic diseases.

Chronic Pruritis
Secondary to Primary Biliary Cholangitis

next
At its core, TH104 harnesses the potent properties of nalmefene, an active molecule renowned for its multifaceted therapeutic effects. By intricately targeting both the µ-opioid receptor and the kappa opioid receptor, TH104 exerts a dual mechanism of action, offering unparalleled efficacy in modulating physiological responses. Additionally, TH104 exhibits the remarkable ability to suppress IL-17 inflammatory cytokine expression, further enhancing its therapeutic potential.

Beyond Our
Primary Indication

next
Our strategic roadmap for TH104 encompasses a rigorous clinical trajectory, with completion of our phase 1 trial. We aim to embark on a phase 2 proof-of-concept study in patients with Primary Biliary Cholangitis (PBC). Leveraging our collective expertise and steadfast commitment to scientific excellence, we anticipate significant milestones in the clinical development of TH104.
Moreover, the versatility of TH104 extends beyond the realm of liver-related disorders, with promising prospects for treating chronic pruritogenic conditions associated with cholestatic liver disease. Furthermore, TH104 exhibits potential applications in addressing a myriad of chronic pruritus in liver-related and non-liver-related diseases, including alcoholic liver disease, metabolic dysfunction-associated steatotic liver disease, and certain types of hepatitis.

Chronic pruritus, a pervasive symptom in liver diseases, emerges as a focal point of our therapeutic endeavors. Recognizing its prevalence across diverse medical contexts, including chronic kidney diseases, hemodialysis, and atopic dermatitis, we remain steadfast in our commitment to advancing innovative solutions that alleviate suffering and enhance the quality of life for patients worldwide.

Explore our Oncology Therapeutics and Pipeline